Navigation Links
Sysmex America Set to Launch New XT-Series(TM) Parameters

FDA-Cleared Parameters Aid in the Diagnosis of Infectious and Inflammatory

Diseases and in Monitoring Iron Deficiency

MUNDELEIN, Ill., Oct. 30 /PRNewswire/ -- Sysmex America, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared Sysmex's Immature Granulocyte (IG) parameter and Reticulocyte Hemoglobin Equivalent (RET-He) parameter for use on the company's XT-Series(TM) Automated Hematology Analyzers for low to mid-volume laboratories, said John Kershaw, President, Sysmex America, Inc. This announcement follows the company's earlier clearances of the same parameters for the Sysmex XE-Series(TM) Automated Hematology Analyzers. Now, clinical laboratories of any size can potentially benefit from enhanced diagnostic information, workflow process improvement, and greater cost-effectiveness, added Kershaw. The IG parameter is now available on both the XT-2000i and the XT-1800i, and the RET-He is available on the XT-2000i Automated Hematology Analyzers. Sysmex is the only company able to provide both of these FDA-cleared parameters.

"As a partner to clinical laboratories nationwide, Sysmex is committed to expanding the clinical utility of our hematology product line. These FDA clearances demonstrate our company's dedication to best-in-class hematology products and empowers clinical laboratories to improve their operations while enhancing patient care," said Kershaw.

About Immature Granulocytes and the Sysmex IG Parameter

The identification of immature granulocytes is primarily of importance in the diagnosis of infectious and inflammatory diseases. The IG parameter on the Sysmex XT-Series Automated Hematology Analyzers provides a quantitative immature granulocyte count for metamyelocytes, myelocytes and promyelocytes by utilizing Sysmex's patented fluorescent flow cytometry technology. This patented technology, used to separate white blood cells into distinct cell clusters, reduces labor-intensive manual WBC differential procedures, and improves turnaround time for results critical to patient care. Prior to Sysmex's automated immature granulocyte counting, manual differential counting of immature granulocytes was slow, expensive and imprecise.

About Reticulocytes and the Sysmex RET-He Parameter

The RET-He parameter is a sensitive measurement of iron available for red cell production. Functional iron available for incorporation into the red cell hemoglobin can be monitored via the RET-He, thus assisting physicians monitoring disease states where iron deficiency is often seen. Less than normal hemoglobin content in reticulocytes, immature red blood cells (RBCs), is an indication of inadequate iron supply relative to demand. The amount of hemoglobin in these reticulocytes also corresponds to the amount of hemoglobin in mature RBCs. The RET-He parameter provides a direct measurement of the mean reticulocyte hemoglobin content. Therefore, it is a useful parameter for assisting physicians with early diagnosis of iron deficiency (iron restricted erythropoiesis), and for optimizing iron therapy.

About Sysmex America, Inc.

Sysmex America, Inc., the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a world leader in clinical laboratory systemization and solutions, including clinical diagnostics, automation and information systems. Serving customers for over 40 years, Sysmex focuses on extending the boundaries of diagnostic science while providing the management information tools that make a real difference in clinical and operational results for people worldwide. For more information about Sysmex, please visit

SOURCE Sysmex America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sysmex Announces Clinical Laboratory Software Name Change
2. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
3. One of Nations Oldest Blood Services Providers Turns to Sysmex America
4. American Oriental Bioengineering, Inc. to Report Third Quarter 2008 Financial Results
5. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
6. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
7. CPC of America Announces Agreement with BC Tech for Manufacture of MedClose(TM) Vascular Closure System
8. Stenum Hospital Does its 600th American Disc Replacement Surgery
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
11. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
Post Your Comments:
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... , November 24, 2015 ... market research report released by Transparency Market Research, the ... at a CAGR of 17.5% during the period between ... Market - Global Industry Analysis, Size, Volume, Share, Growth, ... non-invasive prenatal testing market to reach a valuation of ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... Capricor Therapeutics, Inc. (NASDAQ: ... development and commercialization of first-in-class therapeutics, today announced that ... scheduled to present at the 2015 Piper Jaffray Healthcare ... at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:10/26/2015)... 26, 2015  Delta ID Inc., a company focused ... and PC devices, announced its ActiveIRIS® technology powers the ... F-02H launched by NTT DOCOMO, INC in ... second smartphone to include iris recognition technology, after a ... F-04G in May 2015, world,s first smartphone to have ...
(Date:10/23/2015)... , October 23, 2015 ... announce a mobile plug and play integration of physiological ... tasks SensoMotoric Instruments (SMI) present a ... solutions for eye tracking and physiological data registration. It ... SMI Eye Tracking Glasses 2w and physiological signals ...
(Date:10/22/2015)...  Synaptics (NASDAQ: SYNA ), a leading developer of human ... September 30, 2015. --> --> ... 66 percent over the comparable quarter last year to $470.0 million. ... million, or $0.62 per diluted share. --> ... of fiscal 2016 grew 39 percent over the prior year period ...
Breaking Biology News(10 mins):